These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 24451109

  • 1. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.
    Breast Cancer Res; 2014 Jan 22; 16(1):R7. PubMed ID: 24451109
    [Abstract] [Full Text] [Related]

  • 2. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R, Han J, Liang X, Sun S, Jiang Y, Xia B, Niu M, Li D, Zhang J, Wang S, Wei W, Liu Q, Zheng W, Zhang G, Song Y, Panga D.
    Cell Physiol Biochem; 2017 Jan 22; 43(6):2212-2225. PubMed ID: 29069648
    [Abstract] [Full Text] [Related]

  • 3. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.
    Mol Cancer Res; 2016 Nov 22; 14(11):1054-1067. PubMed ID: 27565181
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Non-canonical AR activity facilitates endocrine resistance in breast cancer.
    Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.
    Endocr Relat Cancer; 2019 Feb 01; 26(2):251-264. PubMed ID: 30557851
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research Consortium (TBCRC 011).
    Clin Cancer Res; 2013 Oct 01; 19(19):5505-12. PubMed ID: 23965901
    [Abstract] [Full Text] [Related]

  • 7. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.
    Mol Cancer Ther; 2017 Aug 01; 16(8):1521-1530. PubMed ID: 28500234
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.
    Clin Cancer Res; 2015 Sep 15; 21(18):4133-42. PubMed ID: 25995342
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM.
    Breast Cancer Res; 2019 Feb 22; 21(1):30. PubMed ID: 30795773
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.
    Prostate; 2013 Sep 22; 73(12):1291-305. PubMed ID: 23765603
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS.
    J Clin Oncol; 2016 Jun 20; 34(18):2098-106. PubMed ID: 26811535
    [Abstract] [Full Text] [Related]

  • 19. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK, Tam T, Wang J, Sadar MD.
    Hum Cell; 2021 Jan 20; 34(1):211-218. PubMed ID: 32954481
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.